Thermo Fisher Scientific, a global leader in serving science, is unveiling a new CHO K-1 cell line and enhanced platform technology that significantly reduce the timeline for Investigational New Drug (IND) filing.

The improvements can decrease lead times from 13 months to just nine, enabling biotech and pharmaceutical companies to navigate the complexities of pre-clinical biologic drug development more efficiently.

The newly introduced CHO K-1 cell line delivers up to 8g/L of protein expression, ensuring higher productivity and enhanced stability. This advancement allows customers to achieve greater efficiency from pre-clinical phases through to commercial development.

“By prioritizing speed to market and simplification of complex processes, Thermo Fisher is enabling a new era of biologics drug development,” said Jennifer Cannon, president of commercial operations, pharma services at Thermo Fisher Scientific.

“Biotech companies, from small to large, as well as pharmaceutical organizations, require faster and more seamless biologics cell line development capabilities. We are proud to offer end-to-end Gene to Patient integrated solutions to accelerate the delivery of life-saving therapies.”

Thermo Fisher’s integrated approach streamlines the drug development process by offering a ‘start here, stay here’ philosophy. This ensures that customers have continuous support throughout every stage of the clinical development journey, from candidate selection to commercialization, eliminating the need for multiple vendors. As a result, companies can save both time and money while simplifying procurement strategies.

With Thermo Fisher’s Accelerator Drug Development, the company says customers gain access to a comprehensive range of services, including Contract Development and Manufacturing Organization (CDMO) solutions, Contract Research Organization (CRO) support, and bioprocessing services. The new CHO K-1 cell line, along with Thermo Fisher’s robust infrastructure, optimizes IND filings, offering a reliable supply chain and consistent support throughout the entire drug development process.